Q3 2025 Revenues of $246.0 million grew 6.7% compared to Q3 2024
Net Loss of $69.8 million
Adjusted EBITDA of $155.1 million increased 9.5% compared to Q3 2024
Adjusted EBITDA Margin of 63.1% versus 61.5% in Q3 2024)
Claritev raises full-year 2025 revenue and Adjusted EBITDA guidance MCLEAN, Va. / Nov 07, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare... Read more
Annual Recurring Revenue (ARR)⁽¹⁾ up 75% YoY to $93.7 million
Total Revenue up 94% YoY to $32.0 million
Adjusted EBITDA⁽¹⁾ up 58% YoY to $7.2 million TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and nine months ended September 30, 2025... Read more
Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025.
Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the... Read more
WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization.
The national partnership seeks to improve clinical de... Read more
Q3 2025 financial results ahead of expectations.
Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.
Expands leadership team to support accelerating growth. WASHINGTON, Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable,... Read more
Revenue of $68 million, up 49%; 53% Member Growth
Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA
Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025.
2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the... Read more
New capability to provide tailored and coordinated care informed by behavioral insights SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings. A new option of prescribing and medication management of anti-obesity... Read more
Reported sales increased 0.7%; organic sales increased 2.7%
Expects full year organic sales growth to be at the high end of +2.0% to +3.0% range
Increases full year adjusted earnings per share outlook to $5.98 to $6.08
Announces 4-year 'Transform for the Future' initiative ST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Highlights Sales increased... Read more
PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025.
Recent Updates Revenue was $149.0 million for the third quarter, compared to $172.9 million in the second quarter, which included $27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding... Read more
MOBILE, Ala. / Nov 06, 2025 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and community healthcare organizations, today announced financial results for the third quarter and nine months ended September 30, 2025.
Third Quarter 2025 Highlights
All comparisons are to the quarter ended September 30, 2024, unless otherwise noted Total bookings of $15.5 million compared to $21.0... Read more
Third Quarter Revenue Delivered at High End of Guidance FRAMINGHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights: Revenue was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024.
Net... Read more
Q3 revenue of $26.1 million, increased 22% year-over-year
Q3 gross profit increased 30% year-over-year to $17.5 million
Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million
Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million
Paid off an incremental $2 million in principal from... Read more
Reports Revenue of $313.3 Million, Reflecting 9.3% Growth
Raises Full Year Guidance to Reflect Continued Strength in Member Engagement
Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing Base
Record $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025
Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY)... Read more
Total revenues of $168.5 million, up 23% year-over-year
Operating cash flow of $93.9 million, up 37% year-over-year
Free cash flow of $91.6 million, up 37% year-over-year SAN FRANCISCO / Nov 06, 2025 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025.
“Our platform continues to grow with new AI tools to save physicians’ time,”... Read more
NEW YORK / Nov 06, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET).
The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger... Read more
HEALWELL achieved quarterly revenue from continuing operations of $30.4 million in Q3-2025, an increase of 354% compared to revenue of $6.7 million generated in Q3-2024. Revenue growth in the quarter was largely driven by the Orion Health acquisition.
During Q3-2025, HEALWELL reported positive Adjusted EBITDA of $0.7 million, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024. This marks the Company's second consecutive quarter of positive Adjusted EBITDA,... Read more
Powered by GeneDx Infinity™ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers the most precise rare disease diagnosis for patients and families GAITHERSBURG, Md. / Nov 06, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC)... Read more
Raises Revenue Guidance, Completes Medsphere Acquisition and Accelerates AI Initiative SOMERSET, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the quarter ended September 30, 2025, and is increasing its full-year 2025 revenue guidance to $117 – $119 million, up from the initial range of $111 – $114 million. CareCloud... Read more
Very Strong Third Quarter and Year-to-Date Performance Across the Business
Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q’24
Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q’24
FY’25 Guidance Raised Above High End for All Key Operating and Financial Metrics ARLINGTON, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter ended September... Read more
Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million
Updates 2025 Financial Guidance NEW YORK / Nov 05, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025.
"Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry’s increasing demand for our leading computational platform,” said Ramy Farid, Ph.D., chief executive... Read more
Vancouver, British Columbia, Canada, November 4, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL3) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Ayla BioScience, Inc., a company formed under the laws of Delaware, USA (“Ayla BioScience”) to enter into an exclusive distribution agreement and a share purchase agreement.
Headquartered in the United States,... Read more
BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third quarter ended September 30. The company’s third quarter earnings report may be viewed at investors.amwell.com.
Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at ht... Read more
Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 SANTA MONICA, Calif. / Nov 04, 2025 / Business Wire / GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025.
Third Quarter 2025... Read more
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada’s behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest... Read more
AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide
Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence... Read more
New applications include Veeva LIMS Basics and PromoMats Basics to drive speed and growth PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechs have selected Veeva Basics to advance operations across clinical, regulatory, and quality. A growing number of biotechs in the U.S. and Europe are establishing a foundation for growth with a simple and standard industry-leading solution that can scale as business... Read more
BOSTON and ROLLE, Switzerland, Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23% year-over-year
Gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year period
Net... Read more
First-quarter total net revenue of $240.0 million (total net revenue excluding Contigo Health* of $234.7 million)
First-quarter GAAP net income from continuing operations of $15.3 million, or $0.21 per fully diluted share
First-quarter adjusted earnings per share of $0.32, excluding Contigo Health* CHARLOTTE, N.C. / Nov 04, 2025 / Business Wire / Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results... Read more
NASHVILLE, Tenn. / Nov 03, 2025 / Business Wire / HealthStream, Inc. (the "Company") (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today results for the third quarter ended September 30, 2025.
Third Quarter 2025 Revenues of $76.5 million in the third quarter of 2025, up 4.6% from $73.1 million in the third quarter of 2024, setting a new Company record for quarterly revenue
Operating income of $7.6 million in the third... Read more
CHICAGO / Nov 03, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference. Jefferies Global Healthcare Conference in London, England – Tuesday, November 18, 2025 at 9:30 am GMT/4:30 am ET/3:30 am CT A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above.
About... Read more
HEALWELL has divested its Polyclinic Family Medicine and Specialty Group of Clinics to WELL Health Clinic Network Inc. ("WELL Clinics"), who has been previously managing these clinics for HEALWELL since January 2024.
HEALWELL has sold its interest in Mutuo Health Solutions Inc. ("Mutuo") to WELLSTAR Technologies Corp. ("WELLSTAR"), so it can better focus on its large enterprise healthcare software and AI business. Mutuo is primarily focused on selling solutions to doctors... Read more
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.
QSP has rapidly become a cornerstone of modern drug discovery and development... Read more
Omnicell delivers strong third quarter financial results
Results exceed previously issued third quarter 2025 guidance on all metrics
Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas / Oct 30, 2025 / Business Wire / Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced... Read more
HEALWELL AI and its subsidiary Orion Health have signed a Memorandum of Understanding (MoU) with Lean Business Services, to jointly explore the development and commercialization of digital health and AI-driven solutions across the Middle East and Orion's global markets.
The MoU leverages complementary strengths across technology, innovation, and market access, focusing on AI driven population health, clinical AI, and data-interoperability.
Initial areas of collaboration... Read more
Q3 revenue growth of 12% year-over-year
Q3 net income of $30.6 million and non-GAAP net income of $67.8 million
Q3 net income margin of 11%; adjusted EBITDA margin of 42%
Raising revenue and adjusted EBITDA guidance for 2025 LEHI, Utah and LOUISVILLE, Ky., Oct. 29, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the third quarter ended September 30, 2025.
"Waystar delivered... Read more
Continued Managed Services Revenue Growth and Focused Expense Management Drives Net Income Levels
Company Reaffirms 2025 Financial Guidance PLANO, Texas / Oct 29, 2025 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced results for the third quarter ended September 30, 2025. In addition, the Company’s Board of Directors declared a regular quarterly dividend of $0.3125 per share, payable on December 9,... Read more
NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2024 (“Third Quarter 2024”).
Highlights Third Quarter 2025 revenue of $626.4 million, down 2% year-over-year
Third Quarter 2025 net loss... Read more
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of the next generation of its high-performance Flex assay, featuring automation-compatible plate-based multiplexing. The new assay delivers cost-effective, highly scalable single... Read more
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technology at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn conference and the European College... Read more
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S.
Organic orders growth was 6% with growth across all segments
Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8%
Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07
Cash flow from operating activities was $593 million; Free cash flow* was $483 million
Excluding tariff... Read more
Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue
Accelerated exome and genome volume growth to 33% year-over-year
Expanded adjusted gross margin to 74% and generated adjusted net income1 of $14.7 million for the third quarter 2025
Raised guidance to deliver between $425 and $428 million in revenue with between 53% to 55% full year growth in exome and genome revenue
Granted FDA Breakthrough Device... Read more
SINGAPORE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), will expand into the Indian market through a strategic master license and representative partnership with SafeRock India Private Limited (“SafeRock... Read more
Data from more than 22,000 newborns reinforce GeneDx’s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice GAITHERSBURG, Md. / Oct 22, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at the International Consortium on Newborn Sequencing (ICoNS), underscoring the company’s leadership in driving genomic newborn... Read more
Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10
Fourth quarter and fiscal year 2025 results to be reported December 1, 2025 RESEARCH TRIANGLE PARK, N.C. / Oct 22, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical... Read more
ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson.
Ms. Knight brings over 30 years of leadership experience in the MedTech... Read more
HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin on October 6, 2025.
HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved remission outcomes, supporting... Read more
Vancouver, British Columbia, Canada, October 20, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has launched a DNA testing program as part of its Nara.Care AI platform for personalized wellness.
Working with a leading developer of DNA testing technologies, the Company will market its Agenta branded DNA testing kits to health-conscious consumers in Canada as part of an initial... Read more
Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader researcher community PLEASANTON, Calif., Oct. 20, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and Anthropic, an AI safety and research company and creator of Claude, today announced a collaboration integrate... Read more
Queen’s and a nationally recognized academic medical center to provide clinical expertise to enhance GE HealthCare’s forthcoming software solution
New software solution will use AI and predictive analytics to recommend actions and help care teams improve quality of care, patient flow, and maximize resources CHICAGO / Oct 20, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health systems—The Queen’s Health... Read more
SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. (“CK Health Plus”), has been granted a Direct Selling License (AJL 932509) (the “License”) by the Malaysian Ministry of Domestic Trade and Cost of Living.
License Approval... Read more
